Farrell Simon - Feb 16, 2023 Form 3 Insider Report for Trevi Therapeutics, Inc. (TRVI)

Role
Chief Commercial Officer
Signature
/s/ Christopher Galletta, attorney-in-fact
Stock symbol
TRVI
Transactions as of
Feb 16, 2023
Transactions value $
$0
Form type
3
Date filed
2/16/2023, 04:26 PM
Next filing
Mar 8, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TRVI Common Stock 20.7K Feb 16, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TRVI Stock Option (right to buy) Feb 16, 2023 Common Stock 75K $3.91 Direct F1
holding TRVI Performance Stock Option (right to buy) Feb 16, 2023 Common Stock 17.5K $3.21 Direct F2
holding TRVI Stock Option (right to buy) Feb 16, 2023 Common Stock 75K $0.51 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on September 22, 2020. The 75,000 shares of common stock underlying the option vested as to 25% of the shares on September 22, 2021 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through September 22, 2024.
F2 Reporting person was granted a performance-based stock option on February 17, 2021, to purchase 17,500 shares of common stock. The option vested based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b/3 PRISM trial of Haduvio (nalbuphine ER) for the treatment of prurigo nodularis, and Phase 2 CANAL trial of Haduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis.
F3 This option was granted on February 11, 2022. The 75,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026.

Remarks:

Exhibit Index: 24.1 Power of Attorney